Literature DB >> 18082077

[Complications and sequelae in acoustic neuroma surgery].

Andrés Coca1, Justo R Gómez, José L Llorente, Juan P Rodrigo, Faustino Núñez, María A Sevilla, Carlos Suárez.   

Abstract

OBJECTIVE: To evaluate the complications and sequelae of acoustic neuroma surgery, according to tumour size. PATIENTS AND
METHOD: A retrospective analysis of 120 patients who underwent microsurgical resection of vestibular schwannomas between November 1994 and September 2006 was undertaken. Tumour size, extent of removal, preservation of facial and cochlear nerves, complications, and sequelae were considered. The degree of hearing preservation after surgery was determined by the Gardner-Robertson classification.
RESULTS: There were 39 small (<1.5 cm), 59 medium (1.5-3 cm), and 22 large tumours (>3 cm). Gross total resection was accomplished in 106 cases (88.3 %). The facial nerve was anatomically and functionally preserved in 103 cases on long-term follow-up (85.4 %). The cochlear nerve was functionally preserved (Gardner-Robertson class 1 and 2) in 54.4 % of the small tumours with useful preoperative hearing. Two patients died due to postoperative complications (mortality rate, 1.6 %), and 15 (12.5 %) developed a CSF leak.
CONCLUSIONS: Despite the progress in the surgical treatment of acoustic neuromas, a considerable rate of complications and sequelae still remains. Therefore, there is a need to balance pros and cons of surgery in each patient according to the concurrent circumstances, as well as to consider other therapeutic strategies such as radiosurgery or a wait-and-see policy.

Entities:  

Mesh:

Year:  2007        PMID: 18082077

Source DB:  PubMed          Journal:  Acta Otorrinolaringol Esp        ISSN: 0001-6519


  1 in total

1.  Intralabyrinthine schwannomas: a new surgical treatment.

Authors:  Daniele Marchioni; Stefano De Rossi; Davide Soloperto; Livio Presutti; Luca Sacchetto; Alessia Rubini
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-20       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.